iifl-logo-icon 1

Themis Medicare Ltd Share Price

276.45
(-1.13%)
Sep 17, 2024|03:14:44 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open279
  • Day's High279.5
  • 52 Wk High287.5
  • Prev. Close279.6
  • Day's Low272
  • 52 Wk Low 142
  • Turnover (lac)341.87
  • P/E76.49
  • Face Value1
  • Book Value31.14
  • EPS3.65
  • Mkt. Cap (Cr.)2,544.45
  • Div. Yield0.18
View All Historical Data
No Records Found

Themis Medicare Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

279

Prev. Close

279.6

Turnover(Lac.)

341.87

Day's High

279.5

Day's Low

272

52 Week's High

287.5

52 Week's Low

142

Book Value

31.14

Face Value

1

Mkt Cap (₹ Cr.)

2,544.45

P/E

76.49

EPS

3.65

Divi. Yield

0.18

Themis Medicare Ltd Corporate Action

14 May 2024

12:00 AM

AGM

Announcement Date: 14 May, 2024

arrow

16 Jul 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

14 May 2024

12:00 AM

BookCloser

arrow

14 May 2024

12:00 AM

Dividend

Dividend Amount: 0.5

arrow

13 May 2023

12:00 AM

Split

arrow

Themis Medicare Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Themis Medicare Ltd SHAREHOLDING SNAPSHOT

17 Sep, 2024|03:17 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 9.61%

Foreign: 9.60%

Indian: 57.54%

Non-Promoter- 0.06%

Institutions: 0.06%

Non-Institutions: 32.78%

Custodian: 0.00%

Share Price

Themis Medicare Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

9.2

9.2

9.2

9.19

Preference Capital

0

0

0

0

Reserves

292.07

272.62

234.28

176.61

Net Worth

301.27

281.82

243.48

185.8

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

230.66

201.58

209.5

216.65

yoy growth (%)

14.42

-3.77

-3.3

6.78

Raw materials

-78.2

-63.18

-71.66

-70.7

As % of sales

33.9

31.34

34.2

32.63

Employee costs

-39.98

-44.27

-44.61

-39.99

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

32.24

18

9.39

16.39

Depreciation

-8.54

-8.26

-7.4

-7.47

Tax paid

-5.62

-2.09

-0.1

-1.6

Working capital

7.89

27.14

18.07

18.93

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

14.42

-3.77

-3.3

6.78

Op profit growth

39.8

39.17

-21.85

4.4

EBIT growth

45.57

45.24

-24.69

5.8

Net profit growth

67.29

71.19

-37.16

-1.8

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

381.76

354.32

394.61

230.67

201.59

Excise Duty

0

0

0

0

0

Net Sales

381.76

354.32

394.61

230.67

201.59

Other Operating Income

0

0

0

0

0

Other Income

23.56

25.12

17.88

13.1

12.37

Themis Medicare Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,866.1

160.64,46,984.11237.820.724,409.7498.75

Divis Laboratories Ltd

DIVISLAB

5,452.2

87.571,45,452.894300.552,063507.93

Cipla Ltd

CIPLA

1,671.8

33.751,34,027.851,055.940.783,752.25346.39

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,453.25

77.741,16,844.734690.812,394201.77

Zydus Lifesciences Ltd

ZYDUSLIFE

1,110.95

25.71,12,260.51,700.80.274,035.4156.19

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Themis Medicare Ltd

Management

Register Office

Registrar Office

Non-Exec & Non-Independent Dir

Rajneesh Anand

Independent Non Exe. Director

Hari Subramaniam

Managing Director & CEO

Sachin D Patel

Executive Chairman

Dinesh S Patel

Independent Non Exe. Director

Manjul Sandhu

Independent Non Exe. Director

Bhaskar Vemban Iyer

Independent Non Exe. Director

Shishir Dalal

Alternate Director

Reena S Patel

Non-Exec. & Independent Dir.

Nikunt Raval

Company Sec. & Compli. Officer

Pradeep Chandan.

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Incorporated in 1969, Themis Medicare Ltd., formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April 93. The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.In Mar.95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, anaesthetic and other segments.Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an anti-bacterial drug, for veterinary use for which it has a confirmed buy-back arrangement with Chinoin, Hungary.The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its Anti-T.B.formulation products thro
Read More

Company FAQs

What is the Themis Medicare Ltd share price today?

Down Arrow

The Themis Medicare Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹276.45 today.

What is the Market Cap of Themis Medicare Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Themis Medicare Ltd is ₹2544.45 Cr. as of 17 Sep ‘24

What is the PE and PB ratio of Themis Medicare Ltd?

Down Arrow

The PE and PB ratios of Themis Medicare Ltd is 76.49 and 9.59 as of 17 Sep ‘24

What is the 52 Week High and Low of Themis Medicare Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Themis Medicare Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Themis Medicare Ltd is ₹142 and ₹287.5 as of 17 Sep ‘24

What is the CAGR of Themis Medicare Ltd?

Down Arrow

Themis Medicare Ltd's CAGR for 5 Years at 69.81%, 3 Years at 39.53%, 1 Year at 63.59%, 6 Month at 28.76%, 3 Month at 28.87% and 1 Month at 6.03%.

What is the shareholding pattern of Themis Medicare Ltd?

Down Arrow

The shareholding pattern of Themis Medicare Ltd is as follows:
Promoters - 67.15 %
Institutions - 0.06 %
Public - 32.79 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp